Zostavax received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) two months ago. The decision is a key milestone towards the granting of a European licence.
Red Door was the hot favourite to secure the Zostavax account, having worked with Sanofi Pasteur MSD in Maidenhead across its vaccines portfolio since 2001. Brands on which the agency already works include Pneumovax (for pneumococcal disease), Rotateq (for rotavirus) and Gardasil (for HPV, which can lead to cervical cancer).
Shingles is potentially a particularly painful disease that can lead to long-lasting complications. It can affect anyone who has previously contracted chickenpox, and occurs most frequently in older adults.